recently that many empirical studies1 relating to the Schumpeterian hypothesis are inappropriate for testing that hypothesis. They observe that Schumpeter can be interpreted as hypothesizing that the elasticity of the value of research and development (R and D) output with respect to firm size is greater than unity. On the other hand, the empirical studies have been concerned with investigating the elasticity of R and D inputs with respect to firm size.
Fisher and Temin demonstrate that a finding that the R and D input elasticity exceeds unity does not imply that the R and D output elasticity exceeds unity also. Given that public policy formulation should be based on tests of the Schumpeter hypothesis rather than on tests of the R and D input elasticity, their point is well taken. Of course, in defense of the empirical studies, it can be argued that data limitations have restricted testing to the R and D input elasticity, and that most of the researchers have been aware that they were not testing the Schumpeter hypothesis.
In a footnote, Fisher and Temin refer to a study of technical change in the pharmaceutical industry that does attempt to test the Schumpeter hypothesis directly.2 This study by Comanor (1965) (Comanor, 1965, p. 190) .
Because the pharmaceutical industry is one of the rare industries for which adequate data are available to test the Schumpeter hypothesis directly, we have attempted to test the hypothesis in that industry for the more recent period, 1965-1970. Another reason for our work was to try to overcome some difficulties in Comanor's analysis that raise ambiguities of interpretation. As we shall report, our work leads to results that are essentially opposite those of Comanor.
Our finding for the 1965-1970 period, that larger firms were "better" at innovation than smaller firms, has another interesting implication. That is, accepting Comanor's findings of the opposite case for the 1955-1960 period, one might be led to hypothesize that the 1962 Amendments to the Food, Drug and Cosmetic Act inadvertently provided an advantage to larger firms. The 1962 Amendments added a "proof-of-efficacy" requirement to the "proofof-safety" requirement of the 1938 Food, Drug and Cosmetic Act. In effect, the 1962 Amendments increased the costs associated with introducing new drugs by requiring extensive tests and evaluations not required previously.
In order to investigate further the effect of the 1962 Amendments, we applied our model to 1955-1960 data. We found that larger firms were "better" at developing new chemical entities in that period also, but their relative advantage over smaller firms was smaller than in the post-1962 period (see footnote 18). The final section is an analysis of the elasticity of technical change with respect to firm size. The total elasticity is shown to consist of two parts -a "direct" and an "indirect" effect of size. The indirect effect is the effect on technical change of the increase in R and-D inputs (induced by an increase in firm size). In this section we make use also of a maximum likelihood estimation technique developed by Tobin (1958) for cases where the dependent variable is limited, as is the case for our sample.
In general, our results show that the elasticity of technical change with respect to firm size increases with size. The elasticity attains the value of unity for firms slightly smaller than the median firm size in our sample. While the indirect effect, discussed above, falls with increases in size, the direct effect rises more than enough to offset this decline.
II. The Comanor Study
Of course, the major difficulty in studies of technical change is to find a proper way of measuring it. Technical change in the pharmaceutical industry primarily takes the form of new product invention and innovation. Generally, our variables are defined similarly to those of Comanor, with one exception. His index of diversification was the product of the number of markets serviced by the firm and the proportion of sales outside the firm's primary market. Our measure is a Herfindahl-type index.
Clearly, our results are statistically much worse than those'of Comanor. We can explain only about half as much of the variation in Y and our t-values, given in parentheses, are lower and indicate that the coefficient of S is the only statistically significant one.4
The influence of firm size on technical change is of central importance in the study. There are in Comanor's specification both positive and negative effects of size on technical change. That is, the coefficient of S is positive and is interpreted as evidence of superior selling capabilities of large firms. The coefficient of R * S is negative and is interpreted as evidence of diseconomies of large scale. While there is no way to disprove this interpretation, a model specifically designed to separate the effect of size as exerted through the alternate channels of organizational and selling capabilities would be preferred.
We have developed a model that appears to meet this requirement. Essentially, we break the measure of technical change into two components and use a two-equation approach. The first equation relates size to the number of new products developed; hence, it permits us to omit the use of size as a proxy for selling capability effects. The second equation relates the average sales per new product to size and thereby permits us to study the selling capability effect separately from R and D considerations.
Ill. The'Two-equation Model
The model can be written simply as the identity
We hypothesize that the two factors on the right-hand side of equation (3) Clearly, the dichotomy may be somewhat artificial. The firm's decisions as to the particular research projects that it embarks upon undoubtedly are influenced to some extent by marketing considerations.5 However, the advantages of the dichotomy in terms of simplicity and directness of interpretation would appear to justify the assumption that the activities can be considered separately. For exapnple, we can disentangle the selling capability effect of firm size from the R and D effect of firm size, the problem that led to difficulties of interpretation in the Comanor work. 4 In preliminary work we ran regressions of Y on R and S for both quadratic and logarithmic specifications. The coefficients of the S variable were generally positive and significant, but other coefficients were usually insignificant. The explained variation was low in all cases, 20% or less. Hence, we concluded that the single equation approach was inappropriate and that some device for disaggregating the innovative process was necessary. 5 On the other hand, discussions with some pharmaceutical executives have led us to believe that decisions regarding research projects to be undertaken often turn upon the skills and knowledge of existing researchers rather than upon a thorough-going analysis of market potentials.
The Sample
In selecting the sample of firms, we were constrained by data limitations. Firms were included in the sample only if data could be obtained for the number of their professional R and D personnel. Generally, this was the most binding constraint since data for other variables were more readily available.
The final sample contains 50 firms. As Comanor noted in his work, the sample is essentially nonrandom and conclusions are applicable only to it and not to the total industry. However, the sample does account for approximately 88%O of total industry sales and therefore should be representative of the total industry.
The size distribution of the 50 firms has a median of $31.9 million of ethical drug sales. The mean of the distribution is $60.6 million and the range is from a low of $0. Finally, we did use annual report data for R and D expenditures in several regressions and obtained similar results to those given later in the paper. For example, we obtained the following version of equation (5 Another important question is whether an R and D staff of a given size operates more efficiently in a larger -firm. One argument is that bigger firms are usually engaged in more activities, so knowledge produced is more likely to be usable. On the other hand, there may be organizational inefficiencies that tend to offset this effect. In order to examine this question we included an interaction variable equal to the product of R and S, or R -S.
A specification well-suited for taking nonlinearities and interactions into account is the logarithmic specification. Unfortunately, the dependent variable in our sample takes the value of zero for 21 of the 50 observations. Since the logarithm of zero does not exist, we did not estimate the logarithmic specification.'3 Equation ( 
The logarithmic specification is appropriate here and no problem is encountered because of zero-valued dependent variables. Although the sample is reduced to 29 observations, this is as it should be. No meaning can be attached to a measure of marketing effectiveness for firms having no new products to sell. 13 As Scherer (1965) has shown, it is dangerous to try to avoid this problem by assigning an arbitrarily small number for zero. The fact that there is a concentration of zeros at the lower limit of the range of the dependent variable also poses a statistical problem. Tobin (1958) has developed a procedure for handling this problem which we shall make use of in a later section.
Our quadratic specification is virtually the same as the one used by Mansfield (1964) in a study of the chemical, petroleum, and steel industries. If the intercept is suppressed, the specification is identical to Mansfield's and can be interpreted as postulating that the expected number of CE's per professional R and D worker is a linear function of R and S. Suppressing the intercept in our study produced no difference in the signs and significance of the coefficients, although the R2 fell by two percentage points.
14 We tried also a second measure of research personnel.
Rather than only the number of professional R and D personnel, we calculated a measure RT equal to the total of professionals, technicians, and auxiliary personnel. When RT was substituted for R, the results were generally inferior. That is, while the algebraic signs were the same, the t-values and the coefficient of determination were lower. For example, the RT version of equation (5) had an R2 of 0.30 (compared to 0.38 for the R version) and the t-value for the coefficient of R S was only 1.13 (compared to 3.40). The other variables were statistically significant. We might also note that the simple correlation coefficient between R and RT is 0.93. 15A concern for multicollinearity led us to examine the partial correlation coefficients between all of the independent variables. In making such an examination we found that the highest coefficient was 0.88 between the square of R and R S. The next highest partial correlation coefficient was only 0.38, between R and R S. Of course, the definitions of the variables insure some induced correlations. Given that the coefficients of these variables were, in most cases, highly significant according to the usual t-test, and that alternate formulations of the variables could not be found to test the desired hypotheses, we have chosen to accept the results in equation (5) The simple correlation coefficient between P and S is 0.93, thereby causing a collinearity problem. Since our primary interest is the effect of size on the dependent variable, we elected to drop P and to interpret S as measuring both P and S.
The coefficients of S and M are both positive, as expected, and highly significant. We might note that spurious correlation between Y and M is probably unimportant because new product sales make up less than 5% of M on the average. Given the good statistical results in equation (7), we shall use it in further analysis.
IV. Analysis of Results
Based upon the empirical results discussed earlier, we shall take equation (5) (8) The marginal product of research personnel increases with size and decreases with R. Thus, our evidence suggests that a given R and D staff is more efficient in developing new chemical entities if it is located in a larger firm. We should note here a possible contributing factor to the finding that size has a positive effect on the marginal product. Our measure of research input is the number of personnel and not the total input of resources into the firm's research activity. A report of the Pharmaceutical Manufacturers Association (1972) indicates that larger firms have higher total R and D expenditures per R and D employee than smaller firms. Hence, to some unknown extent, the variable S in our regressions may be serving as a proxy for these higher expenditures.
Equation ( (10) represents the "direct" effect of an increase in size on CE's developed. 16 The investigation of the relationship between size and R and D input has been pursued by several authors (see references in footnote 1). In this study various functional forms of the R,S association were explored. A quadratic specification indicated that R increases with S at an increasing rate, although the coefficient of S was not significant. The log-log specification presented in equation (9) proved statistically superior, and was chosen for deriving the elasticity estimates. We might add that the elasticity of R with respect to S indicated in equation (9) is quite consistent with the findings of others.
17The use of equation (9) implicitly raises the question of the proper estimation technique for the basic CE equation. That is, one could consider the CE equation and equation (9) to be part of a simultaneous system of equations, thereby calling for the use of a simultaneous equation estimation technique. We have not elected to follow such an approach here because our interest is primarily confined to the "production function-type" relations and the specification of a complete simultaneous equation model is beyond the scope of this study. For an examination (and rejection) of the possibility that technical change influences R and D staff rather than the reverse, see Comanor (1965 OLS and LIM estimates of the elasticity of CE with respect to firm size, or e(CE,S). Thus, the LIM estimates of e (CE,S) are lower for smaller sizes and higher for larger sizes than the OLS estimates. More importantly, the general tendency of larger sizes to have higher elasticities is unaffected.
Size and Technical Change
We have argued previously that society should be more may not yet be a problem in ethical drugs.
